Silva Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
For the nine months, sales was BDT 477.25 million compared to BDT 582.5 million a year ago. Net loss was BDT 10.6 million compared to net income of BDT 53.39 million a year ago. Basic loss per share from continuing operations was BDT 0.08 compared to basic earnings per share from continuing operations of BDT 0.39 a year ago.